The Venture Codex

Participated · Equity · Dec 2017

Precision Medicine Group (PMG) provides specialized services and an integrated infrastructure to support pharmaceutical and life-sciences companies developing precision-medicine drugs and diagnostics. The company supports development, approval and commercialization efforts across drugs and diagnostics. PMG was formed in 2012 and is headquartered in Bethesda, Maryland, with more than 1,000 employees and 22 locations in the U.S., Canada and Europe. Management says the company’s services address key challenges facing biopharmaceutical and diagnostic companies. The new capital will fund expansion of PMG’s global footprint and provide additional scale to accelerate development and commercial success for customers. No revenue or other financial metrics were disclosed in the article.

Participated · Equity · Apr 2013

Precision for Medicine is a Bethesda, Maryland–based specialty services company that supports pharmaceutical and life sciences companies through product development and commercialization. Led by co‑founder and executive chairman Ethan Leder, the company provides an integrated infrastructure to help clients demonstrate economic value, validate outcomes, and build differentiation within the healthcare marketplace. It applies science, technology, expertise and project execution to advance patient‑centric solutions from discovery through commercialization. The company received a $75M investment from TPG Growth. It will use the proceeds to grow both organically and via acquisitions. Precision for Medicine provides services and infrastructure to support life science companies developing new products, including regulatory sciences, clinical development, commercialization, and product strategy expertise. The company is building a comprehensive platform of specialized development and commercialization services intended to speed approval, reduce costs, and optimize market launch. It also offers next‑generation bioservices such as biorepository, sample management, and cellular products from facilities in Frederick and Gaithersburg, MD. Formed in 2012 and based in Chevy Chase, MD, Precision employs over 130 people. The company secured a $150M private equity financing and intends to use the proceeds for acquisitions and development. Backers in the financing included Oak Investment Partners, J.H. Whitney and Company, and Precision’s co‑founders Ethan D. Leder and Mark P. Clein.

Participated · Series C · Sep 2011

Authentix develops authentication and brand protection solutions, including a complete Banknote Sensor Platform with security inks, security taggants, and high-speed sensors that assess banknote authenticity and fitness. The company serves governments and Fortune 500 clients across oil & gas, pharmaceuticals, spirits, and personal care verticals. Authentix reports having helped recover $11 billion in lost revenue for clients and has supported six central banks since entering the banknote industry in 2006. The funding will support expansion of its Currency business unit, specifically its high-speed banknote sensor platforms, while continuing investments in core authentication and brand protection capabilities. Authentix also plans to pursue strategic acquisitions of complementary technologies to extend its offerings and geographic reach. The company has operated since 2003 and is publicly presenting from Dallas in this announcement.